Delivery Devices Crucial To Success, Lifespan Of Asthma/COPD Meds
This article was originally published in The Gray Sheet
Sales of Merck’s Singulair fell off the molecular patent cliff, but not Glaxo’s still-mighty Advair. Why? Because it has an additional patent protecting its delivery device.
You may also be interested in...
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.